// App-Quantinova.ai

TPS1136 : A randomized phase II trial of upfront docetaxel and vinorelbine followed by either maintenance oral vinorelbine or observation in patients with HER2-negative locally advanced (LA) or metastatic (M) breast cancer (BC).

Researchers

Presenter

  • Fadi Sami Farhat

Principal Investigators

  • Marwan Ghosn

  • Cynthia Mourad

  • Ahmed Othman

  • Mayssam El-Mouhebb

  • Joseph Gergi Kattan

  • Nizar Bitar

  • Moussa Dehaini

  • Georges Y. Chahine

Medical Centers

  • Lebanese University, Beirut, Lebanon

  • Hammoud Hospital University Medical Center, Saida, LebanonFaculty of Medicine, Saint-Joseph University, Beirut, LebanonSahel General Hospital, Beirut, Lebanon

  • Hotel-Dieu de France University Hospital, Beirut, Lebanon

  • Cancer Research Group- Collaborative Group, Beirut, Lebanon

  • Pierre Fabre Medicament, Beirut, Lebanon

  • Hotel-Dieu de France University Hospital, Beirut, Lebanon

  • Labib Medical Center, Saida, Lebanon

Locations

  • Lebanon

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Human epidermal growth factor receptor 2

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Vinorelbine

  • Docetaxel

Outcome

  • Unknown

Study Design

  • randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Laboratoires Pierre Fabre

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved